| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 12,708,489 | |||
| Prepaid expenses and other current assets | 123,934 | |||
| Total current assets | 12,832,423 | |||
| Property and equipment, net | 23,919 | |||
| Total assets | 12,856,342 | |||
| Accounts payable | 1,034,951 | |||
| Accrued expenses | 819,381 | |||
| Warrant liability | 175 | |||
| Total current liabilities | 1,854,507 | |||
| Total liabilities | 1,854,507 | |||
| Common stock, 0.001 par value 500,000,000 shares authorized at september 30, 2025 and december 31, 2024 and 3,585,972 and 174,104 issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 3,586 | |||
| Additional paid-in-capital | 57,906,530 | |||
| Accumulated deficit | -46,908,281 | |||
| Total stockholders' equity | 11,001,835 | |||
| Total liabilities and stockholders' equity | 12,856,342 | |||
REVELATION BIOSCIENCES, INC. (REVB)
REVELATION BIOSCIENCES, INC. (REVB)